1 Study Title

- 2 Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19:
- 3 A Prospective Phase II Clinical Trial

4 Authors

- 5 Danyal Ibrahim, MD, MPH, Trinity Health Of New England, Hartford, Connecticut, USA
- 6 Latha Dulipsingh, MD, Diabetes Center, Saint Francis Hospital, Hartford, Connecticut, USA
- 7 Lisa Zapatka, MSN, Trinity Health Of New England, Hartford
- 8 Reginald Eadie, MD, Trinity Health Of New England, Hartford
- 9 Rebecca Crowell, PhD, Research Department, Saint Francis Hospital, Hartford
- 10 Kendra Williams, BS, Research Department, Saint Francis Hospital, Hartford
- 11 Dorothy B. Wakefield, MS, Research Department, Saint Francis Hospital, Hartford
- 12 Lisa Cook, BSN, Diabetes Center, Saint Francis Hospital, Hartford
- 13 Jennifer Puff, BSN, Diabetes Center, Saint Francis Hospital, Hartford
- 14 Syed A. Hussain, MD Trinity Health Of New England, Hartford

15 **Corresponding author**

- 16 Danyal Ibrahim, M.D., M.P.H.
- 17 Trinity Health Of New England
- 18 114 Woodland Street
- 19 Hartford, CT 06105
- 20 Tel 860-794-5886
- 21 Fax 860-714-5769
- 22 Email: dibrahim@trinityhealthofne.org
- 23

24 Abstract

We conducted a prospective single-arm open-label phase II clinical trial assessing the 25 safety and efficacy of convalescent plasma in hospitalized COVID-19 patients. Convalescent 26 plasma with sufficient IgG titer (1:320) obtained from recovered donors was administered to 27 28 adult patients with either severe or critical COVID-19 illness. Primary outcomes were adverse events in association with plasma administration, and hospital mortality. Secondary outcomes 29 30 included disease progression, recovery, length of stay, and hospital discharge. Of the 38 patients 31 included in the analysis, 24 (63%) recovered and were discharged, and 14 (37%) died. Patients 32 who received convalescent plasma early in the disease course (severe illness group) as compared 33 to the patients that received convalescent plasma later in disease progression (critical illness 34 group) had significantly lower hospital mortality 13% vs 55% (p<0.02) and shorter mean 35 hospital length of stay 15.4 vs 33 days (p < 0.01). One patient experienced a transient transfusion reaction. No other adverse effects of convalescent plasma infusion were observed. Our results 36 37 suggest that convalescent plasma is safe and has the potential for positive impact on clinical 38 outcomes including recovery and survival if given to patients early in the course of COVID-19 disease. 39

40 Keywords

Adult; Humans; Length of Stay; Patient Discharge; Hospital Mortality; Respiratory Distress
Syndrome, Adult; Prospective Studies; COVID-19; severe acute respiratory syndrome
coronavirus 2; Hospitals; Respiration; Ventilation; Plasma; Disease Progression;
Immunoglobulin G; Plasma; COVID-19 serotherapy; Clinical Trial, Phase II

46 Introduction

47	Coronavirus Disease 2019 (COVID-19) is a viral respiratory syndrome caused by severe
48	acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of July 24, 2020, this novel virus
49	was discovery in Wuhan City, Hubei Province, China, in December 2019, confirmed cases have
50	risen to more than 14,000,000 worldwide and more than 600,000 people have died (1).
51	Currently, no cure or standard treatment for COVID-19 exists.
52	The majority of people with COVID-19 experience an asymptomatic, mild, or
53	manageable course of disease (2, 3). The most common symptoms include fever, cough, fatigue,
54	dyspnea, headache, diarrhea, fatigue, myalgia, and/or loss of taste and smell (4, 5). However,
55	19% of those who are infected with the virus become severely or critically ill (2). Life
56	threatening illness occurs when the virus triggers a progressive hyper-immune response or
57	"cytokine storm" progressing to acute respiratory distress syndrome (ARDS), cardiac injury,
58	thrombotic complications, septic shock and/or organ failure (6-9). Estimated mortality among
59	patients admitted to the intensive care unit (ICU) with severe or critical illness ranges from
60	34.8% to 41.6% (10, 11). Risk of death and disease severity increase with older age, obesity and
61	chronic disease such as hypertension, diabetes and cardiovascular disease (7-9, 12-14).
62	In March of 2020, The US Food and Drug Administration (FDA) solicited investigational
63	new drug applications to test the safety and efficacy of convalescent plasma therapy for patients
64	with severe or life-threatening COVID-19 (15). Convalescent plasma is derived from the blood
65	of recovered patients and is a rich source of antibodies. When administered to patients who are
66	ill with the same disease, the plasma may aid recovery by conferring passive immunity and
67	neutralizing the pathogen (15) . The therapy showed promise during outbreaks of other novel
68	viral respiratory syndromes, including two caused specifically by coronavirus (SARS-CoV in
69	2003 and Middle Eastern Respiratory Syndrome (MERS) in 2012) (16, 17). Data showed that

70	convalescent plasma might be most effective when given earlier in the course of disease, but
71	research was limited to small observational studies and much remains unknown (16, 17).
72	Preliminary data from clinical trials and observational studies targeting COVID-19
73	suggest that administration of convalescent plasma may reduce mortality, hospital length of stay,
74	and time on mechanical ventilation with minimal adverse side-effects in patients with severe or
75	life-threatening disease (18-23). Consistent with earlier studies, treatment may be most
76	efficacious for severe COVID-19 when administered closer to symptom onset (21-25). The
77	purpose of this study is to describe the course of illness among 38 patients hospitalized with
78	severe or life-threatening COVID-19 who received convalescent plasma as part of an FDA-
79	approved Phase 2 clinical trial. Specifically, the study will assess their hospital course in the
80	context of demographics, disease onset, symptomology, illness severity, and disease progression.
81	Material and Methods
82	This study is an FDA-approved prospective single-arm open-label Phase II clinical trial
83	(NCT04343261) assessing the safety and efficacy of convalescent plasma (IND #19805) on the
84	clinical course of adult patients hospitalized with severe COVID-19.
85	https://clinicaltrials.gov/ct2/show/NCT04343261?term=plasma&cond=COVID-
86	<u>19&cntry=US&draw=3&rank=19</u>
87	Patients
88	Subjects were recruited from four regional hospitals in Connecticut and Massachusetts
89	between period of April 20, 2020 and June 8, 2020. Patients were considered eligible for the
90	study if they were between the ages of 18 and 90, hospitalized, severely or critically ill with
91	confirmed COVID-19 through nasopharyngeal swab real time PCR (RT-PCR). Illness severity
92	was defined as follows: Mild COVID-19 was defined as symptoms with no clinical signs of

moderate, severe, or critical disease; moderate illness was defined as respiratory rate ≥ 20 breaths per minute and oxygen saturation > 93%; severe illness was defined as any of the following: respiratory frequency ≥ 30 /minute, blood oxygen saturation $\leq 93\%$, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, and lung infiltrates > 50% within 24 to 48 hours; evidence of critical illness included respiratory failure, septic shock, or multi-organ dysfunction or failure (*15*, *26*).

99 Subjects who met eligibility criteria were referred by their treating physicians. Patients 100 were enrolled regardless of previous treatment or therapies for COVID-19, including 101 experimental medications and therapies administered off-label. Informed consent was provided 102 by either the patient or the patient's legally authorized representative (LAR). Once a patient or 103 the patient's LAR provided informed consent and the patient's ABO blood type was determined, 104 compatible convalescent plasma was administered in 2 consecutive 200 mL infusions. Each unit was transfused for the duration of 1 hour, 1 to 2 hours apart. If the patient received plasma with 105 106 undetectable antibodies, the patient was re-dosed with a unit of plasma with adequate antibody 107 titer (1:320). Recipients were monitored and all adverse reactions or events were recorded whether or not they were related to the plasma infusion. The protocol was approved by the 108 109 Trinity Health Of New England Institutional Review Board (#SFH-20-23).

110

Convalescent Plasma

111 Convalescent plasma was obtained from adult donors who were confirmed positive and 112 had recovered from SARS-CoV-2. All donors screened negative for the virus using a nasal swab 113 (RT-PCR) and had IgG titers >6.5 arbitrary units per mL (AU/mL; equivalent to 1:320). Plasma 114 was collected by apheresis at an established blood donation center following standard operating

procedures and 21 CFR 630.10 requirements. Plasma was frozen within 24 hours of collectionand labeled for investigational use and ABO typing.

117 Data and Data Sources

118 Demographic, clinical and outcomes data were prospectively collected from electronic patient medical records at each of the four hospitals. Descriptive data included sex, age, race, 119 ethnicity, smoking status, functional status, comorbidities, living situation, and means of arrival 120 to the hospital. Initial presentation to the Emergency Department included self-reported 121 122 symptoms, vital signs, degree of respiratory distress, and need for oxygen supplementation and 123 resuscitation. Initial chest X-ray findings, and laboratory markers of sepsis, inflammatory response, immune deficiency and organ dysfunction were recorded. The clinical course during 124 hospital stay was prospectively captured by tracking changes in oxygenation (FiO2), need for 125 126 invasive ventilation, ICU level care and types of essential medications given. Patient clinical 127 status progression and recovery were prospectively monitored by capturing days on invasive 128 ventilation, intubation, extubation, discharge alive, and death during hospitalization.

129

Outcomes and Data Analysis

Primary clinical outcomes were rate of adverse events associated with convalescent plasma administration, and hospital mortality. Secondary outcomes included disease progression, recovery, length of hospital stay, and hospital discharge. Primary and secondary clinical outcomes were compared between 2 groups based on severity of illness (*15, 26*) at the time of plasma infusion: 1) patients with severe illness, who had not progressed to ARDS at the time of enrollment, and 2) patients whose condition had progressed to critical illness at the time of enrollment. Patients were excluded from the analysis if they were transferred to another acute

137	hospital; did not receive convalescent plasma with adequate antibody titer; or care was
138	withdrawn and patient received comfort care only within 5 days of plasma administration.
139	Statistical Analysis
140	Descriptive statistics included means, medians and proportions as appropriate based on
141	variable, sample size and distribution. Descriptive variables included demographic
142	characteristics, clinical parameters, and time from illness onset and hospitalization to plasma
143	transfusion. Due to the small sample size, both parametric and nonparametric statistics were used
144	in the analysis as appropriate. Continuous variables were compared using t-tests, and categorical
145	variables using Chi-square analyses and Fisher's exact test when cell-sizes were small. SAS
146	software version 9.4 (SAS Institute Inc., Cary, NC, USA) was used for analyses. Outcomes were
147	considered statistically significant at $p < 0.05$.
148	Results
148 149	Results Plasma Recipients
149	Plasma Recipients
149 150	Plasma Recipients A total of 46 patients (Figure 1) with RT-PCR-confirmed COVID-19 were enrolled in the
149 150 151	Plasma Recipients A total of 46 patients (Figure 1) with RT-PCR-confirmed COVID-19 were enrolled in the study. Eight 8/46 (17%) patients were excluded from the analysis for the following reasons: 2
149 150 151 152	Plasma Recipients A total of 46 patients (Figure 1) with RT-PCR-confirmed COVID-19 were enrolled in the study. Eight 8/46 (17%) patients were excluded from the analysis for the following reasons: 2 received convalescent plasma with no detectable antibody titer; 1 was transferred to another
149 150 151 152 153	Plasma Recipients A total of 46 patients (Figure 1) with RT-PCR-confirmed COVID-19 were enrolled in the study. Eight 8/46 (17%) patients were excluded from the analysis for the following reasons: 2 received convalescent plasma with no detectable antibody titer; 1 was transferred to another hospital; 5 were made comfort care only (CMO) and medical care was withdrawn within 5 days
149 150 151 152 153 154	Plasma Recipients A total of 46 patients (Figure 1) with RT-PCR-confirmed COVID-19 were enrolled in the study. Eight 8/46 (17%) patients were excluded from the analysis for the following reasons: 2 received convalescent plasma with no detectable antibody titer; 1 was transferred to another hospital; 5 were made comfort care only (CMO) and medical care was withdrawn within 5 days of plasma administration. The remaining patients (n=38) included in this analysis received
149 150 151 152 153 154 155	Plasma Recipients A total of 46 patients (Figure 1) with RT-PCR-confirmed COVID-19 were enrolled in the study. Eight 8/46 (17%) patients were excluded from the analysis for the following reasons: 2 received convalescent plasma with no detectable antibody titer; 1 was transferred to another hospital; 5 were made comfort care only (CMO) and medical care was withdrawn within 5 days of plasma administration. The remaining patients (n=38) included in this analysis received convalescent plasma with adequate antibody titer of 1:320 (30 received 2 units, 5 were re-dosed

black, 32% white, and 34% were Hispanic; 56% of the patients were from Connecticut, 37%

160 from Harford County, 19% New Haven County, and 42% were from Hampden County, 161 Massachusetts (Table 1). More than 68% had been diagnosed with hypertension and nearly half (47.4%) with diabetes mellitus; overall, 31.5% had three or more comorbidities (Table 2). As 162 163 shown in Table 3, mean days from onset of symptoms to hospitalization was 7.3 days (95% CI 6.4-8.2), with the most common symptoms at admission being fever, cough and dyspnea. With 164 the exception of one patient who arrived in critical condition, subjects presented initially to the 165 hospital with moderate to severe COVID-19 pneumonia without evidence of ARDS or requiring 166 invasive ventilation support at the time of admission (Table 4). The most common laboratory 167

abnormalities on admission included severe rise in inflammatory markers (C-reactive protein

169 (CRP) $\geq 10 \text{ mg/dL}$) (66%), lymphopenia (absolute lymphocyte count<1,000 per microliter)

170 (50%), and hyponatremia (Na<135 mEq/L) (47%) – see Table 4.

171

Severe and Critical Illness Groups

At the time of plasma infusion, 16 patients (42%) met criteria for severe illness. These 172 173 patients were enrolled in the study and received convalescent plasma earlier in their hospital and disease course on average 4.6 days (95% CI 2.9-6.3) following hospital admission, and 12.6 days 174 (95% CI 10-15.2) following symptoms' onset while on high-flow oxygen supplementation prior 175 to any evidence of ARDS. The remaining 22 patients (58%) met the criteria for critical illness at 176 177 the time of convalescent plasma therapy. They enrolled in the study and received convalescent plasma later in their hospital and disease course on average16.4 days (95% CI 13-19.8) following 178 hospital admission, and 23.1 days (95% CI 19.5-26.7) following symptoms' onset after 179 180 developing ARDS and had been on ventilation support for an average of 10.6 days (95% CI 7.3-181 13.9).

182	The two cohorts were comparable in demographics; comorbidities and home
183	medications; pre-illness functional status; onset of symptoms to seeking hospital care; initial
184	clinical presentation and findings; initial disease severity; and the care they received during their
185	hospitalization including essential medications (see Tables 1-5). Clinically, hyponatremia on
186	initial hospital presentation was more prevalent in the severe illness group (p=0.047).
187	Vasopressors (p<0.01), hydroxychloroquine (p<0.01), and antibiotics (p<0.01) were more
188	frequently used during hospitalization in the critical illness group. Renal replacement therapy
189	was utilized at higher rate in the critical illness group but did not reach statistical significance
190	(p=0.05).
191	Primary Outcomes
192	One patient in the severe illness group experienced a transient transfusion reaction (fever
193	and hematuria) within 2 hours of plasma infusion. No other adverse effects of convalescent
194	plasma infusion were observed. Of the 38 patients included in the analysis, 24 (63%) recovered
195	and were discharged from the hospital, and 14 (37%) died. Patients who died included two in the
196	severe illness group and 12 in the critical illness group. The difference in mortality (13% severe
197	vs 55% critical) was statistically significant (p=0.02). Overall, patients who survived (n=24)
198	regardless of disease severity at time of infusion received convalescent plasma earlier in their

- 199 course of disease (mean 15.3 days, SD 6.9) and hospital stay (8.4 days, SD 6.8) compared to
- those who died (n=14) with mean durations of (24.5 days, SD 9.6), (16.6 days, SD 9.5) the set of t
- 201 respectively.
- 202 Secondary Outcomes

Among patients with severe illness at the time of convalescent plasma therapy, 25% (4/16) progressed to ARDS after receiving convalescent plasma (Table 5). Three of the 4

205 required mechanical ventilation and 2 of the 4 died. One of those patients received convalescent 206 plasma 18 days following onset of symptoms and died of refractory shock in ICU while on 207 ventilator support. The other patient received convalescent plasma 16 days following symptom 208 onset, developed respiratory failure secondary to ARDS, and was placed on comfort measures at the request of the family. The remainder (14/16, 88%) did not progress to ARDS, recovered with 209 resolution of COVID-19 pneumonia, and were discharged from the hospital. 210 211 In the patients with critical illness at the time plasma therapy, 10/22 (45%) recovered 212 with resolution of ARDS and restoration of organ function and left the hospital. Of the 12/22

213 (55%) who died, 6 died of refractory shock while on ventilator support with evidence of

214 pneumoperitonium in 4 of them; 3 patients died of refractory respiratory failure with terminal

extubation; 2 died of complications of upper airway edema; and 1 patient died of an acutecardiac complication.

Mean hospital length of stay was 25.6 days (95% CI 20.8-30.4) (Table 5). Length of stay 217 218 was significantly shorter in the severe illness group (15.5 days, 95% CI 9.3-21.6) compared to 219 patients in the critical illness group (33.0 days, 95% CI 27.3-38.7) (p<0.01). Statistical analyses showed that patients treated earlier in the course of COVID-19 disease (severe group) had 220 significantly lower hospital mortality (p=0.02) and shorter hospital length of stay (p<0.01) after 221 222 convalescent plasma therapy compared to patients that were treated later in their disease course in presence of ARDS (critical group) (Table 5). Other prognostic factors that were significantly 223 224 associated with good clinical outcomes included shorter durations between symptoms onset and 225 convalescent plasma administration (p<0.01), and hospital admission and administration of 226 convalescent plasma (p<0.01).

227 **Discussion**

228 Among this group of hospitalized patients with severe or critical COVID-19 who 229 received convalescent plasma with adequate antibody titer, only one patient experienced a 230 transient transfusion reaction. This low rate of adverse event secondary to convalescent plasma 231 therapy is consistent with recent published literature (22, 23). The overall hospital mortality among our patients was 37%. However, patients who received convalescent plasma early in the 232 233 disease course (severe illness group) as compared to the patients that received convalescent 234 plasma later in disease progression (critical illness group) had significantly lower hospital 235 mortality 13% vs 55% (p<0.02) and shorter mean hospital length of stay 15.4 vs 33 days 236 (p<0.01). In addition, only 4 patients (25%) in the severe illness group developed ARDS, with 3 of them needing invasive ventilation support following convalescent plasma therapy. Two of the 237 3 recovered and were discharged. 238

239 It is important to understand the timeline and dynamics of COVID-19 hospitalizations in 240 Connecticut and Western Massachusetts at the time when we launched our research study. Our 241 study patients presented initially to the hospital with an average of 7.3 days (95% CI 6.4-8.2) 242 from symptoms' onset to hospitalization, and 97 % (37/38) of the patients had moderate to severe disease without evidence of ARDS or urgent need for invasive ventilation support upon 243 admission. By the time we enrolled our first patient in late April 2020, hospitals participating in 244 245 the study were at their peak COVID-19 census, with a large number of seriously ill patients who had been hospitalized for an average of 2 weeks, and were not improving with supportive care or 246 247 medications (see Table 5). Some of those patients deteriorated and needed ICU care and 248 ventilator support for an average of 7 days prior to enrollment. Many had severe lung damage 249 and multi-organ failure. In the early phase of our study, physicians enrolled mostly patients in 250 this critical illness category. In majority of cases, patients died due to secondary irreversible

251 complications of COVID-19. As our study progressed, physicians started enrolling patients 252 earlier in their disease course and hospital stay before respiratory status deterioration. 253 Upon admission to the hospital, the two cohorts were similar in their demographic 254 characteristics, pre-illness functional status, comorbidities, initial clinical presentation to the hospital, and initial disease severity. However, at the time of convalescent plasma administration, 255 the groups diverged on their disease severity and duration from disease onset to plasma therapy. 256 257 The patients in our study who received convalescent plasma earlier in their disease course 258 (severe illness group) had significantly more favorable primary and secondary clinical outcomes 259 as compared to the critical group. We speculate that convalescent plasma given earlier in the disease course arrested the progression to irreversible complications like ARDS or organ failure. 260 In addition, we found that patients who survived in both groups had shorter times between onset 261 262 of symptoms and convalescent plasma administration compared to those that died. The literature suggests that convalescent plasma may be more beneficial when 263 264 administered sooner to disease onset (16, 17). Data recently published on COVID-19 suggested 265 favorable clinical outcomes when convalescent plasma is given earlier in the course of disease (21-25). Our finding is consistent with the literature that treating patient with COVID-19 disease 266 with convalescent plasma within the first two weeks following symptom onset may promote 267 recovery (27). Perhaps earlier treatment with convalescent plasma allows antibodies to neutralize 268 the virus before irreversible complications (19). Vasopressor, antibiotics and renal replacement 269 therapy were utilized at higher rate in the critical group – we speculate that these therapies were 270 271 proxies for serious and refractory complications among critically ill patients that could not be 272 reversed by administration of convalescent plasma. We also speculate that the difference in 273 hydroxychloroquine utilization between the two groups is likely a reflection of the change of

274	evidence in association with hydroxychloroquine efficacy and safety and subsequent change in
275	practice during our study. Important limitations in this study include open-label, no control group
276	and modest sample size. However, this early report is important as it meaningfully contributes to
277	the questions whether convalescent plasma is safe and it sheds light on important factors that are
278	associated with favorable outcomes including recovery and survival.
279	Conclusions
280	For patients with severe or critical COVID-19 disease, convalescent plasma from
281	recovered COVID-19 patients is safe and has the potential for positive impact on clinical
282	outcomes including recovery and survival if given early in course of disease. Our study makes a
283	strong case for the importance of pursing a randomized placebo control trial focused on enrolling
284	patients early in the course of their disease to further explore experimentally the efficacy and
285	effectiveness of convalescent plasma in Covid-19.
286	Acknowledgments
287	Funding
288	This study was supported by funds from Trinity Health Of New England, a not-for-profit
289	healthcare organization.
290	Authorship
291	All named authors meet the International Committee of Medical Journal Editors (ICMJE)
292	criteria for authorship for this article, take responsibility for the integrity of the work as a whole,
293	and have given their approval for this version to be published.
294	We thank the donors, patients and their families for contributing to this work. We also
295	thank the physicians from the Trinity Health Of New England Hospitals who enrolled patients in
296	this study at Johnson Memorial Hospital, Stafford, Connecticut (Ian Tucker); Mercy Medical

297	Center, Springfield Massachusetts (Robert Roose, Laurie Loiacono, and Vikram Sondi); Saint
298	Francis Hospital and Medical Center, Hartford Connecticut (Phillip Roland, Jessica Abrantes-
299	Figueiredo, Daniel Gerardi, Prashant Grover, and Gagandeep Singh), and St. Mary's Hospital in
300	Waterbury, Connecticut (Paul Porter and Bethel Shiferaw); the New York Blood Center and
301	Rhode Island Blood Center for assisting with the plasma collection process; Ernst J. Schaeffer
302	and Margaret R Diffenderfer, Boston Heart Diagnostics in Massachusetts, for serology testing;
303	Collen Lima, Jessica McKenzie, Lisa Cook, Jennifer Puff, Mary Onoroski, and Patricia Nabors
304	for their work with donors, specimen collection and plasma delivery; Kelly Batch, Donna
305	Sobinski, Cynthia Considine, Brian Masthay, Christina Maxwell and Robert Wilke from the
306	Trinity Health Of New England EPIC team for building the study in the electronic health record
307	and assisting with study implementation. This study was funded and supported by Trinity Health
308	Of New England, Hartford, Connecticut.
309	Disclosures
310	The authors declare that they have conflict of interests and no competing interests.

311 Compliance with ethics guidelines

312 The study protocol was approved by the Trinity Health Of New England Institutional Review

Board (#SFH-20-23). The research study was performed in accordance with the Helsinki

314 Declaration of 1964, and its later amendments. Informed consent was provided by either the

315 patient or the patient's legally authorized representative (LAR).

316 Data availability

The datasets generated during and/or analyzed during the current study are available from the

318 corresponding author on reasonable request.

319 **References**

- 320. <u>https://coronavirus.jhu.edu/map.html</u>.
- 322. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease
- 322 (COVID-19). 2020. <u>https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-</u>
- 323 <u>management-patients.html</u>.
- 324. He J, Guo Y, Mao R, Zhang J. Proportion of asymptomatic coronavirus disease 2019
- 325 (COVID-19): a systematic review and meta-analysis. J Med Virol. 2020. Epub 2020/07/21.
- 326 Accessed 7/26/2020
- 3274. Park M, Cook AR, Lim JT, Sun Y, Dickens BL. A Systematic Review of COVID-19
- Epidemiology Based on Current Evidence. J Clin Med. 2020;9(4):967.
- 325. Gautier JF, Ravussin Y. A New Symptom of COVID-19: Loss of Taste and Smell. Obesity
- 330 (Silver Spring). 2020;28(5):848.
- 336. Lu L, H Zhang, M Zhan, J Jiang, H Yin, DJ Dauphars, et al. Preventing Mortality in
- 332 COVID-19 Patients: Which Cytokine to Target in a Raging Storm? Front Cell Dev Biol.

333 2020;8:677.

- 334. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunologic features
- in severe and moderate Coronavirus Disease 2019. J Clin Invest. 2020;130(5):2620-9.
- 338. Deng Y, Liu W, Liu K, Fang YY, Shang J, Zhou L, et al. Clinical characteristics of fatal and
- recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective
- study [published online ahead of print, 2020 Mar 20]. Chin Med J (Engl) [Internet].
- 339 Accessed May 15, 2020.
- 349. Liu W, Tao ZW, Wang L, Yuan ML, Liu K, Zhou L, et al. Analysis of factors associated
- 341 with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin
- 342 Med J (Engl). 2020;133(9):1032-8.

- 10. Armstrong RA, Kane AD, Cook TM. Outcomes from intensive care in patients with
- 344 COVID-19: a systematic review and meta-analysis of observational studies. Anaesthesia.
- 345 2020. Epub 2020/06/30. Accessed 7/24/2020.
- 11. Quah P, Li A, Phua J. Mortality rates of patients with COVID-19 in the intensive care unit: a
- 347 systematic review of the emerging literature. Crit Care. 2020;24(1):285.
- 12. Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of patients with
- 349 COVID-19 in Shanghai, China. J Infect [Internet]. 2020 Mar PMC7102530]; 80(5):[e1-e6
 350 pp.].
- 13. Bonow RO, Hernandez AF, Turakhia M. Hydroxychloroquine, Coronavirus Disease 2019,
- and QT Prolongation [published online ahead of print, 2020 May 1]. JAMA Cardiol
- 353 [Internet]. Accessed 5/15/2020.
- 14. Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors
- Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US.
- 356 JAMA Intern Med. 2020. Epub 2020/07/15. Accessed 7/24/2020.
- 15. U.S. Department of Health and Human Services Food and Drug Administration (FDA).
- Investigational COVID-19 Convalescent Plasma: Emergency INDs. March 2020.
- 359 <u>https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-</u>
- 360 <u>exemption-ide-process-cber/investigational-covid-19-convalescent-plasma- (accessed April</u>
- 361 <u>10, 2020.</u>
- 16. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The
- 363 effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment
- 364 of severe acute respiratory infections of viral etiology: a systematic review and exploratory
- 365 meta-analysis. J Infect Dis. 2015;211(1):80-90.

- 36d7. Sun M, Xu Y, He H, Zhang L, Wang X, Qiu Q, et al. Potential effective treatment for
- 367 COVID-19: systematic review and meta-analysis of the severe infectious disease with
- 368 convalescent plasma therapy. Int J Infect Dis. 2020. Epub 2020/07/04. Accessed 7/24/2020.
- 3698. Zhang L, Pang R, Xue X, Bao J, Ye S, Dai Y, et al. Anti-SARS-CoV-2 virus antibody levels
- in convalescent plasma of six donors who have recovered from COVID-19. Aging (Albany
- 371 NY). 2020;12(8):6536-42.
- 37219. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma
- therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A [Internet]. 2020 Apr;
- 374 (2020;117(17) 9490-6.
- 3720. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients
- 376 With COVID-19 With Convalescent Plasma. JAMA 2020; 323(16):1582 1589.
- 37721. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of Convalescent Plasma
- 378 Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening
- 379 COVID-19: A Randomized Clinical Trial. JAMA. 2020. Epub 2020/06/03. Accessed
- 380 7/23/2020.
- 3822. Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, et al. Early
- safety indicators of COVID-19 convalescent plasma in 5,000 patients. J Clin Invest. 2020.
- 383 Epub 2020/06/11. Accessed 7/24/2020.
- 38423. Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, et al. Safety
- 385 Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clinic
- 386 Proceedings. 2020.

24. Hartman WR, Hess AS, Connor JP. Hospitalized COVID-19 Patients treated with	387	24.	Hartman	WR.	Hess AS.	Connor	JP.	Hos	pitalized	COVID	-19	Patients	treated	wit
---	-----	-----	---------	-----	----------	--------	-----	-----	-----------	-------	-----	----------	---------	-----

- Convalescent Plasma in a Mid-size City in the Midwest. Res Sq. 2020. Epub 2020/07/14.
- 389Accessed 7/24/2020.
- 390 25. Salazar E, Perez KK, Ashraf M, Chen J, Castillo B, Christensen PA, et al. Treatment of
- Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma. Am J Pathol.
- 392 2020. Epub 2020/05/27. Accessed 7/24/2020.
- 26. U.S. Department of Health and Human Services Food and Drug Administration (FDA).
- 394 COVID-19: Developing Drugs and Biological Products for Treatment or Prevention
- 395 Guidance for Industry, May 2020. <u>https://www.fda.gov/media/137926/download</u> (accessed
- 396July 26, 2020)
- 27. Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al.
- 398 Convalescent plasma in Covid-19: Possible mechanisms of action [published online ahead
- of print, 2020 May 5]. Autoimmun Rev. 2020:102554. Epub 2020/05/05. Accessed
- 400 6/21/2020.

402 Table 1 Demographic characteristics of convalescent plasma recipients*

	Overall, n=38	Severe, 16 (42)	Critical, 22 (58)	p value
Age, Mean (SD)	63 (12)	65 (11)	61 (13)	0.30
Age Less than 70	28 (74)	11 (69)	17 (77)	0.56
Gender (female)	18 (47)	8 (50)	10 (46)	0.78
Race				0.92
Black	13 (34)	6 (38)	7 (32)	
White	12 (32)	5 (31)	7 (32)	
Other	13 (34)	5 (31)	8 (36)	
Ethnicity (Hispanic)	13 (34)	4 (25)	9 (41)	0.31
County				0.45
Hampden County	15 (40)	7 (44)	8 (36)	
Hartford County	14 (37)	7 (44)	7 (32)	
New Haven County	8 (21)	2 (12)	6 (27)	
Tolland County	1 (3)	0 (0)	1 (5)	
Insurance - Medicaid or Self-pay	8 (21)	4 (25)	4 (18)	0.19
Marital Status - Married	17 (45)	7 (44)	10 (45)	

403

404 *Values are no. (%) except as indicated

406	Table 2	Comorbidities and home medications of convalescent plasma recipients*
-----	---------	---

	Overall, n=38	Severe, 16 (42)	Critical, 22 (58)	p value
BMI, Mean (SD)	33.6 (6.5)	34.4 (7.9)	33 (5.4)	0.53
Smoking Status (Smoker)	4 (11)	2 (13)	2 (9)	0.87
ABO Blood Type - A Group	9 (24)	5 (31)	4 (18)	0.48
Comorbidities				
COPD/ Asthma	15 (39)	7 (44)	8 (36)	0.64
Obstructive Sleep Apnea	5 (13)	1 (6)	4 (18)	0.37
Hypertension	26 (68)	9 (56)	17 (77)	0.17
Diabetes Mellitus	18 (47)	8 (50)	10 (45)	0.78
Coronary Artery Disease	5 (13)	1 (6)	4 (18)	0.37
Chronic Kidney Disease	5 (13)	2 (13)	3 (14)	1.00
Cancer	4 (11)	2 (13)	2 (9)	1.00
VTE	3 (8)	2 (13)	1 (5)	0.56
Multiple Comorbidities				0.46
0-2	26 (68)	12 (75)	14 (64)	
3-7	12 (32)	4 (25)	8 (36)	
Home Medications				
ARB**	11 (29)	6 (38)	5 (23)	0.32
ACEi**	8 (21)	3 (19)	5 (23)	1.00
CCB**	9 (24)	2 (13)	7 (32)	0.25
NSAIDs**	14 (37)	6 (38)	8 (36)	0.94
Steroids	4 (11)	1 (6)	3 (14)	0.63

407

408 409 *Values are no. (%) except as indicated. **ARB=angiotensin II receptor blocker; ACEi=angiotensin converting enzyme inhibitor;

CCB=calcium channel blocker; NSAIDs=non-steroidal anti-inflammatory drugs.

411 Table 3 Characteristics and symptoms at presentation to the hospital among convalescent plasma recipients*

	Overall, n=38	Severe, 16 (42)	Critical, 22 (58)	p value
Mode of arrival – EMS**	28 (74)	11 (69)	17 (77)	0.56
Patient origin				0.68
Home	32 (84)	13 (81)	19 (86)	
Skilled nursing facility	6 (16)	3 (19)	3 (14)	
Functional status - Independent of ADLs**	33 (87)	13 (81)	20 (91)	0.63
Source of exposure to COVID-19				0.30
Family	10 (26)	3 (19)	7 (32)	
Long term care facility	5 (13)	3 (19)	2 (9)	
Work	6 (16)	1 (6)	5 (23)	
No known source	17 (45)	9 (56)	8 (36)	
Onset of symptoms (days), mean (SD)	7.3 (2.8)	8 (3.1)	6.7 (2.6)	0.17
Symptoms reported on presentation to hospital				
Fever (temperature ≥38° C or subjective)	30 (79)	14 (88)	16 (73)	0.43
Cough	35 (92)	15 (94)	20 (91)	1.00
Dyspnea	37 (97)	15 (94)	22 (100)	0.42
Headache	9 (24)	5 (31)	4 (18)	0.45
Loss of Appetite	17 (45)	6 (38)	11 (50)	0.52
Fatigue	24 (63)	11 (69)	13 (59)	0.74
Body aches	13 (34)	5 (31)	8 (36)	1.00
Chest Pain	9 (24)	4 (25)	5 (23)	0.87
GI symptoms	17 (45)	7 (44)	10 (45)	0.92
Loss of taste or smell	3 (8)	2 (13)	1 (5)	0.56
Confusion	6 (16)	4 (25)	2 (9)	0.22

⁴¹²

413 *Values are no. (%) except as indicated. #Bold text = statistically significant. **EMS=emergency medical services; ADLs=activities of

414 daily living.

415 Table 4 Clinical presentation at admission of convalescent plasma recipients*

	Overall, n=38	Severe, 16 (42)	Critical, 22 (58)	p valu
Disease severity (FDA Classification) on admission				0.14
Moderate	5	4 (25)	1 (5)	
Severe	32	12 (75)	20 (90)	
Critical	1	0 (0)	1 (5)	
RA O2Sat ≤ 85%**	18 (47)	6 (38)	12 (55)	0.30
Oxygen support on admission				0.61
Low Flow Nasal	27 (71)	11 (69)	16 (72)	
High Flow Nasal	10 (26)	5 (31)	5 (23)	
Invasive Ventilation	1 (3)	0 (0)	1 (5)	
Chest X-ray with typical COVID-19 findings**	35 (92)	14 (88)	21 (95)	0.56
Febrile (temperature ≥38° C)	10 (26)	6 (38)	4 (18)	0.27
Hypotension**	1 (3)	0 (0)	1 (5)	1.00
Lymphopenia**	19 (50)	9 (56)	10 (45)	0.51
Rise in sepsis markers**	13 (34)	4 (25)	9 (41)	0.31
Severe rise in inflammatory markers**	25 (66)	10 (63)	15 (68)	0.71
Transaminitis**	9 (24)	4 (25)	5 (23)	1.00
AKI**	10 (26)	7 (44)	3 (14)	0.06
Hyponatremia**	18 (47)	11 (69)	7 (32)	0.047
Hypokalemia**	7 (18)	1 (6)	6 (27)	0.20
Troponin leak**	7 (18)	2 (13)	5 (23)	0.68

416

*Values are no. (%) except as indicated. [#]Bold text = statistically significant. **RA O2Sat=room-air oxygen saturation; Chest X-ray
 with typical COVID-19 findings=multifocal peripheral consolidation and/ or multifocal founded opacities and nodules; Hypotension=
 mean arterial blood pressure less than 60 mm Hg; Lymphopenia=absolute lymphocyte count less than 1,000 per microliter; Rise is
 sepsis markers=serum lactate>2.2 mmol/L; Severe rise in inflammatory markers=C-reactive protein≥10 mg/dL; Transaminitis= 5x or

greater rise in serum ALT level; AKI=acute kidney injury when eGFR<60 mL/min/1.73 sq meters; Hyponatremia=serum sodium less
 than 135 mEq/L; Hypokalemia=serum potassium less than 3.5 mEq/L; Troponin leak=serum troponin>0.04 ng/mL.

424 Table 5 Patient Outcomes and Hospital Course*

	Overall, n=38	Severe 16 (42)	Critical, 22 (58)	p valu
Outcome				
Mortality	14 (37)	2 (13)	12 (55)	0.02
Length of stay (days), mean (SD)	26 (15)	15.4 (11.6)	33 (12.9)	<0.01
Symptom onset to CP (days), mean				
(SD)	18.7 (9.0)	12.6 (5.3)	23.1 (8.6)	<0.0
Symptom onset to CP admin ≤ 15 days	17 (45)	13 (81)	4 (18)	<0.0
Hospital days prior to CP admin, mean				
(SD)	11.4 (8.8)	4.6 (3.4)	16.4 (8.1)	<0.0
Hospital days after CP admin, mean				
(SD)	14.2 (11.5)	10.9 (10.5)	16.5 (11.9)	<0.0
ARDS** prior to CP admin	22 (58)	0 (0)	22 (100)	<0.0
ARDS** during hospitalization	26 (68)	4 (25)	22 (100)	<0.0
Invasive mechanical ventilation	25 (66)	3 (19)	22 (100)	<0.0
Ventilator days, mean (SD)	20.3 (10.3)	16 (12.1)	21 (10.2)	0.45
Other interventions and medications				
Renal Replacement Therapy	9 (24)	1 (6)	8 (36)	0.05
Antibiotics	32 (84)	10 (63)	22 (100)	<0.0
Antifungals	4 (11)	0 (0)	4 (18)	0.12
Azithromycin	16 (42)	4 (25)	12 (55)	0.07
Hydroxychloroquine	17 (45)	3 (19)	14 (64)	<0.0
IL-6 Inhibitors	10 (26)	3 (19)	7 (32)	0.47
Remdesivir	4 (11)	3 (19)	1 (5)	0.29
Vasopressors	20 (53)	3 (19)	17 (77)	<0.0
Steroids	22 (58)	7 (44)	15 (68)	0.13
Anticoagulants	31 (82)	13 (81)	18 (82)	1.00
Zinc	17 (45)	6 (38)	11 (50)	0.44

⁴²⁵

426 *Values are no. (%) except as indicated. [#]CP = convalescent plasma; **ARDS = Acute respiratory distress syndrome; bold text =

427 statistically significant.




Figure 1 Flowchart of Patients and Outcomes